Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PPI-461 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A | ACTIVE_COMPARATOR | PPI-461 50 mg or placebo |
| Cohort B | ACTIVE_COMPARATOR | PPI-461 100 mg or placebo |
| Cohort C | ACTIVE_COMPARATOR | PPI-461 200 mg or placebo |
| Name | Type | Description |
|---|---|---|
| PPI-461 | DRUG | capsule, oral, once daily for 3 days |
| Placebo | DRUG | capsules, oral, once daily for 3 days |
Eligibility Criteria: * Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years post-menopausal and are required to take a pregnancy test) * Body Mass Index (BMI) 18 - 32 kg/m2 * Chronically infected with hepatitis C genotype-1 virus * Serum HCV RNA \> ...
PPI-461 is an investigational small molecule being developed for the treatment of chronic genotype 1 hepatitis C virus infection. It is a Phase 1 drug candidate that has completed a clinical trial in patients with this condition.
PPI-461 is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BCRX. The company is conducting clinical research on this investigational drug for chronic genotype 1 hepatitis C virus infection.
PPI-461 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied for the treatment of chronic genotype 1 hepatitis C virus infection.
PPI-461 has been studied in one completed Phase 1 clinical trial, identified as NCT01247194, titled "A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1." This trial enrolled 24 patients and was conducted in the United States, Denmark, and the United Kingdom.
PPI-461 is the investigational name for this drug candidate developed by BioCryst Pharmaceuticals. No alternative names have been reported for this compound in the available clinical trial information.